Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price shot up 21.1% on Thursday . The stock traded as high as $12.97 and last traded at $12.86, with a volume of 516,907 shares trading hands. The stock had previously closed at $10.62.

Several research firms have recently weighed in on AQXP. Canaccord Genuity reissued a “buy” rating and set a $22.00 price target on shares of Aquinox Pharmaceuticals in a report on Wednesday, August 17th. Needham & Company LLC initiated coverage on Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They issued a “buy” rating and a $25.00 price objective for the company. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Finally, Jefferies Group upped their price objective on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Aquinox Pharmaceuticals presently has an average rating of “Buy” and an average price target of $19.86.

The firm’s market capitalization is $208.95 million. The stock’s 50-day moving average price is $9.08 and its 200-day moving average price is $8.44.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. Analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($2.08) EPS for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.